Indivior Pharmaceuticals Inc (INDV) Stock Analysis
Is INDV a good investment?
Indivior Pharmaceuticals Inc (INDV) has a Plutrex AI rating of 87.0/100 as of May 26, 2026, indicating a Strong Buy consensus. The stock is not classified as halal-compliant. Key strength: Exceptional undervaluation with PEG ratio 0.51 vs industry 1.16, trading at 56% discount to growth-justified value. Main concern: Near-term growth deceleration with 9.2% next-year EPS growth vs industry 20.2%, indicating potential momentum slowdown.
Investment Summary
INDV presents a compelling investment opportunity with exceptional fundamentals reinforced by perfect news sentiment. The company trades at a PEG ratio of 0.51 (56% discount to industry 1.16), indicating significant undervaluation despite superior profitability metrics including 83.1% gross margin (47% premium to industry 56.4%) and 46.1% operating margin (211% premium to industry 14.8%). With $175M in cash, positive free cash flow of $44.3M, and analyst consensus target of $49.71 representing 32.5% upside, the fundamentals strongly support the investment thesis backed by unanimous positive analyst revisions and share buyback program.
Key Strengths
- Exceptional undervaluation with PEG ratio 0.51 vs industry 1.16, trading at 56% discount to growth-justified value
- Superior profitability leadership with 83.1% gross margin (47% industry premium) and 46.1% operating margin (211% premium)
- Perfect news sentiment (100/100) with $175M share buyback, analyst estimate revisions, and strong Q1 performance
Key Concerns
- Near-term growth deceleration with 9.2% next-year EPS growth vs industry 20.2%, indicating potential momentum slowdown
- Missing critical financial metrics (ROE and debt-to-equity) limiting complete financial health assessment
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
INDV demonstrates exceptional financial metrics with gross margin of 83.1% vs industry 56.4%, operating margin of 46.1% vs industry 14.8%, and net margin of 19.4% vs industry 9.8%. The company maintains strong liquidity with $175M cash and generates $44.3M in free cash flow. Growth profile shows 19.2% revenue growth and projected 5-year EPS growth of 19.1%, though near-term EPS growth of 9.2% lags industry 20.2%. The PEG ratio of 0.51 vs industry 1.16 indicates the stock trades at half its growth-justified valuation, while PE ratio of 19.01 represents 19% discount to industry 23.49. Missing ROE and debt-to-equity ratios limit complete assessment but available metrics strongly favor the investment.
News Sentiment
Indivior Pharmaceuticals is experiencing a remarkable turnaround story that has Wall Street buzzing with optimism. The opioid addiction treatment specialist has captured analyst attention with a series of positive developments that suggest the company has found its footing after years of challenges. Recent headlines highlight analysts predicting substantial upside potential, with some forecasting gains of over 27% as the stock breaks out of previous trading ranges. The company's financial performance has been particularly impressive, with analysts raising their earnings estimates across the board - a clear sign of growing confidence in management's execution. Adding fuel to the bullish sentiment, Indivior announced a significant $175 million accelerated share repurchase agreement with Barclays, demonstrating management's confidence in the company's future prospects and commitment to returning value to shareholders. New clinical studies showing improved patient adherence to their monthly injectable buprenorphine treatment are providing additional validation of their product portfolio's effectiveness. For everyday investors, this represents a compelling opportunity in the growing addiction treatment market, where Indivior appears to be emerging as a leader with both the financial strength and clinical evidence to capitalize on increasing demand for effective opioid addiction therapies.
Risk Assessment
Primary risk is near-term growth deceleration with 9.2% EPS growth vs 20.2% industry average, potentially limiting momentum. Missing debt metrics create uncertainty about leverage profile. However, exceptional profitability margins, strong cash position, and significant undervaluation provide substantial downside protection. Perfect news sentiment and analyst support mitigate execution risks.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is INDV a halal stock?
No, Indivior Pharmaceuticals Inc (INDV) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for INDV?
Indivior Pharmaceuticals Inc (INDV) has a Plutrex AI rating of 87.0/100 with a Strong Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is INDV a good investment?
According to Plutrex AI, INDV has a Strong Buy rating (87.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in INDV?
US stocks like INDV can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in INDV?
Plutrex AI identifies the main risks for INDV by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.